A major focus of the guideline is earlier intervention through healthy lifestyle changes, starting in childhood. Early consideration of pharmacotherapy in youth with familial hypercholesterolemia (FH) ...

In this week’s View, Dr. Eagle looks at the differential effect of bisoprolol versus verapamil in nonobstructive hypertrophic cardiomyopathy (HCM) treatment. He then explores lower heart failure (HF) ...

Hospital admissions for heart attacks increase after exposure to lower air temperature and cold spells, according to a study published today in JACC, the flagship journal of the American College of ...

The American College of Cardiology (ACC), the American Heart Association and nine other leading medical associations, today issued an updated guideline for the management of dyslipidemia—abnormal ...

With technological advances like artificial intelligence (AI), machine learning and digital health tools moving from concept into clinical practice, a State-of-the-Art Review in JACC: Asia offers a ...

Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves symptoms in men and women with a common type of heart failure that has had few therapeutic options ...

The American College of Cardiology is pleased to offer fellows in training, medical residents, doctoral or medical students and Cardiovascular Team students (nurses, pharmacists, PAs, and ...

As the new year begins, the landscape of cardiovascular medicine is undergoing a remarkable transformation, driven by groundbreaking technologies and innovative approaches that promise to ...

About 50% of U.S. adults will develop high BP during their lifetime. High BP is the most prevalent and modifiable risk factor for cardiovascular disease and all-cause mortality. The overarching BP ...

Food supplementation for patients following a heart failure (HF)-related hospitalization was both feasible and acceptable and associated with clinically meaningful improvement in quality of life ...

Beta-blocker therapy following myocardial infarction (MI) was the primary focus of a hot line session at ESC Congress 2025. Study investigators presented findings from the REBOOT-CNIC and ...

The SGLT2 inhibitor empagliflozin did not lower the risk of a first hospitalization for heart failure (HF) or death from any cause among patients with an increased risk for HF following acute ...